ArticleArthritis research & therapy2026
Elucidating the mechanism of taurine in alleviating osteoarthritis progression based on bioinformatics, machine learning algorithm, and experimental validation.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFerroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, plays a pivotal role in chondrocyte death and the pathogenesis of osteoarthritis (OA). Taurine, a sulfur-containing amino acid with established anti-inflammatory and anti-ferroptotic properties, has been implicated in joint protection; however, its potential to mitigate OA progression by targeting ferroptosis mechanisms remains largely unexplored.
methodsRNA sequencing was performed on normal and OA knee joint cartilage tissues to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) was used to screen for OA-related modules, and ferroptosis-related targets were retrieved from public databases. Intersecting genes from the DEGs, WGCNA modules, and ferroptosis targets underwent pathway enrichment analysis. Taurine target genes were predicted via multiple databases, and machine learning algorithms were applied to identify hub genes. A nomogram model was constructed to evaluate diagnostic accuracy. Immune infiltration was assessed using the CIBERSORT algorithm. Furthermore, in vitro experiments involving interleukin-1 beta (IL-1β)-stimulated chondrocytes and in vivo studies using a destabilization of the medial meniscus (DMM) mouse model were conducted to validate the effects of taurine.
resultsMachine learning analysis identified four key hub genes: CSRNP1, CTH, OSBPL3, and CITED2. CTH was selected as the primary focus due to the effect of taurine on its expression in IL-1β-stimulated chondrocytes. In vitro assays demonstrated that taurine treatment specifically reversed the IL-1β-induced downregulation of CTH. Mechanistic studies showed that taurine directly bound to the CTH protein and attenuated IL-1β-induced ferroptosis by restoring CTH expression, thereby increasing glutathione (GSH) levels, reducing iron accumulation and lipid peroxidation, and upregulating solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). Consistently, taurine alleviated cartilage degradation and synovial inflammation in DMM-induced OA mice, whereas these benefits were reversed by the CTH inhibitor propargylglycine (PAG).
conclusionTaurine exerted significant chondroprotective effects, at least in part, by directly targeting CTH to suppress chondrocyte ferroptosis, thereby ameliorating OA progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.